Trifexis

Country: European Union

Language: Icelandic

Source: EMA (European Medicines Agency)

Active ingredient:

spinosad, milbemycin oxím

Available from:

Eli Lilly and Company Limited

ATC code:

QP54AB51

INN (International Name):

spinosad, milbemycin oxime

Therapeutic group:

Hundar

Therapeutic area:

Sníklaeyðandi vörur, skordýraeitur og repellents, Endectocides

Therapeutic indications:

Fyrir meðferð og koma í veg fló (Ctenocephalides sus) sníkjudýra í hunda þar einn eða fleiri eftir vísbendingar þarf samtímis: fyrirbyggja heartworm sjúkdómur (L3, L4 Dirofilaria immltís);fyrirbyggja angiostrongylosis með því að draga úr stig af sýkingu með óþroskaður fullorðinn (L5) Angiostrongylus vasorum;meðferð maga þráðormurinn sýkingar af völdum lögð (L4, óþroskaður fullorðinn, L5) og fullorðinn Ancylostoma caninum), roundworms (óþroskaður fullorðinn L5, og fullorðinn Toxocara canis og fullorðinn Toxascaris andreoletti) og whipworm (fullorðinn Trichuris vulpis).

Product summary:

Revision: 4

Authorization status:

Aftakað

Authorization date:

2013-09-19

Patient Information leaflet

                                Lyfið er ekki lengur með markaðsleyfi
19
B. FYLGISEÐILL
Lyfið er ekki lengur með markaðsleyfi
20
FYLGISEÐILL FYRIR:
TRIFEXIS 270MG/4,5 MG TUGGUTÖFLUR FYRIR HUNDA
TRIFEXIS 425MG/7,1 MG TUGGUTÖFLUR FYRIR HUNDA
TRIFEXIS 665MG/11,1 MG TUGGUTÖFLUR FYRIR HUNDA
TRIFEXIS 1040/17,4 MG TUGGUTÖFLUR FYRIR HUNDA
TRIFEXIS 1620 MG/27 MG TUGGUTÖFLUR FYRIR HUNDA
1.
HEITI OG HEIMILISFANG MARKAÐSLEYFISHAFA OG ÞESS FRAMLEIÐANDA
SEM BER ÁBYRGÐ Á LOKASAMÞYKKT, EF ANNAR
Markaðsleyfishafi:
Eli Lilly and Company Ltd
Elanco Animal Health
Priestley Road
Basingstoke
Hampshire
RG24 9NL
Bretland
Framleiðandi sem ber ábyrgð á lokasamþykkt:
Eli Lilly and Company Ltd
Speke Operations
Fleming Road
Liverpool
L24 9LN
Bretland
2.
HEITI DÝRALYFS
Trifexis 270mg/4,5 mg tuggutöflur fyrir hunda (3,9 – 6,0 kg)
Trifexis 425mg/7,1 mg tuggutöflur fyrir hunda (6,1 – 9,4 kg)
Trifexis 665mg/11,1 mg tuggutöflur fyrir hunda (9,5 – 14,7 kg)
Trifexis 1040/17,4 mg tuggutöflur fyrir hunda (14,8 – 23,1 kg)
Trifexis 1620 mg/27 mg tuggutöflur fyrir hunda (23,2 – 36,0 kg)
spinosad/milbemýsin oxím
3.
VIRK(T) INNIHALDSEFNI OG ÖNNUR INNIHALDSEFNI
VIRK INNIHALDSEFNI:
Hver tafla inniheldur:
Trifexis 270 mg/4,5 mg
spinosad 270 mg/4,5 mg milbemýsin oxím
Trifexis 425 mg/7,1 mg
spinosad 425 mg/7,1 mg milbemýsin oxím
Trifexis 665 mg/11,1 mg
spinosad 665 mg/11,1 mg milbemýsin oxím
Trifexis 1040 mg/17,4 mg
spinosad 1040 mg/17,4 mg milbemýsin oxím
Trifexis 1620 mg/27 mg
spinosad 1620 mg/27,0 mg milbemýsin oxím
Töflurnar eru brúnleitar til brúnar, kringlóttar tuggutöflur.
Eftirfarandi listi sýnir númer og fjölda
dælda eftir styrkleika töflunnar:
Trifexis 270 mg/4,5 mg töflur:
4333 og 2 dældir
Trifexis 425 mg/7,1 mg töflur:
4346 og 3 dældir
Trifexis 665 mg/11,1 mg töflur:
4347 og engar dældir
Trifexis 1040 mg/17,4 mg töflur:
4349 og 4 dældir
Lyfið er ekki lengur með markaðsleyfi
21
Trifexis 1620 mg/27 mg töflur:
4336 og 5 dældir
4.
ÁBENDING(AR)
Til meðhöndlunar og varnar gegn flóasmiti (
_Ctenocephalides 
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                Lyfið er ekki lengur með markaðsleyfi
1
VIÐAUKI I
SAMANTEKT Á EIGINLEIKUM LYFS
Lyfið er ekki lengur með markaðsleyfi
2
1.
HEITI DÝRALYFS
Trifexis 270 mg/4,5 mg tuggutöflur fyrir hunda (3,9 – 6,0 kg)
Trifexis 425 mg/7,1 mg tuggutöflur fyrir hunda (6,1 – 9,4 kg)
Trifexis 665 mg/11,1 mg tuggutöflur fyrir hunda (9,5 – 14,7 kg)
Trifexis 1040 /17,4 mg tuggutöflur fyrir hunda (14,8 – 23,1 kg)
Trifexis 1620 mg/27 mg tuggutöflur fyrir hunda (23,2 – 36,0 kg)
2.
INNIHALDSLÝSING
VIRK INNIHALDSEFNI:
Hver tafla inniheldur:
Spinosad
Milbemýsin oxím
Trifexis 270 mg/4,5 mg
270 mg
4,5 mg
Trifexis 425 mg/7,1 mg
425 mg
7,1 mg
Trifexis 665 mg/11,1 mg
665 mg
11,1 mg
Trifexis 1040 mg/17,4 mg
1040 mg
17,4 mg
Trifexis 1620 mg/27 mg
1620 mg
27,0 mg
Sjá lista yfir öll hjálparefni í kafla 6.1.
3.
LYFJAFORM
Tuggutöflur.
Brúnleitar til brúnar, kringlóttar, tvíkúptar töflur merktar
með íþrykktu númeri á annarri hliðinni og
dældum á hinni.
Eftirfarandi listi sýnir númer og fjölda bóla eftir styrkleika
töflunnar:
Trifexis 270 mg/4,5 mg töflur:
4333 og 2 dældir
Trifexis 425 mg/7,1 mg töflur:
4346 og 3 dældir
Trifexis 665 mg/11,1 mg töflur:
4347 og engar dældir
Trifexis 1040 mg/17,4 mg töflur:
4349 og 4 dældir
Trifexis 1620 mg/27 mg töflur:
4336 og 5 dældir
4.
KLÍNÍSKAR UPPLÝSINGAR
4.1
DÝRATEGUNDIR
Hundar.
4.2
ÁBENDINGAR FYRIR TILGREINDAR DÝRATEGUNDIR
Til meðhöndlunar og varnar gegn flóasmiti (
_Ctenocephalides felis_
) hjá hundum einungis ef ein eða
fleiri af eftirfarandi ábendingum er til staðar samtímis:

forvarnir gegn hjartaormaveiki (L3, L4
_Dirofilaria immitis_
),

forvarnir gegn angiostrongylosis með því að draga úr sýkingum af
völdum óþroska fullvaxinna
(L5)
_Angiostrongylus vasorum,_

meðferð við þráðormasmiti í meltingarvegi af völdum bitorms
(L4, óþroska fullvöxnum (L5) og
fullvöxnum
_Ancylostoma caninum_
), spóluorms (óþroska fullvöxnum L5, og fullvöxnum
_Toxocara _
_canis _
ásamt fullvöxnum
_Toxascaris leonina_
) og svipuor
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 08-10-2018
Summary of Product characteristics Summary of Product characteristics Bulgarian 08-10-2018
Public Assessment Report Public Assessment Report Bulgarian 08-10-2018
Patient Information leaflet Patient Information leaflet Spanish 08-10-2018
Public Assessment Report Public Assessment Report Spanish 08-10-2018
Patient Information leaflet Patient Information leaflet Czech 08-10-2018
Public Assessment Report Public Assessment Report Czech 08-10-2018
Patient Information leaflet Patient Information leaflet Danish 08-10-2018
Public Assessment Report Public Assessment Report Danish 08-10-2018
Patient Information leaflet Patient Information leaflet German 08-10-2018
Public Assessment Report Public Assessment Report German 08-10-2018
Patient Information leaflet Patient Information leaflet Estonian 08-10-2018
Public Assessment Report Public Assessment Report Estonian 08-10-2018
Patient Information leaflet Patient Information leaflet Greek 08-10-2018
Public Assessment Report Public Assessment Report Greek 08-10-2018
Patient Information leaflet Patient Information leaflet English 08-10-2018
Public Assessment Report Public Assessment Report English 08-10-2018
Patient Information leaflet Patient Information leaflet French 08-10-2018
Public Assessment Report Public Assessment Report French 08-10-2018
Patient Information leaflet Patient Information leaflet Italian 08-10-2018
Public Assessment Report Public Assessment Report Italian 08-10-2018
Patient Information leaflet Patient Information leaflet Latvian 08-10-2018
Public Assessment Report Public Assessment Report Latvian 08-10-2018
Patient Information leaflet Patient Information leaflet Lithuanian 08-10-2018
Summary of Product characteristics Summary of Product characteristics Lithuanian 08-10-2018
Public Assessment Report Public Assessment Report Lithuanian 08-10-2018
Patient Information leaflet Patient Information leaflet Hungarian 08-10-2018
Summary of Product characteristics Summary of Product characteristics Hungarian 08-10-2018
Public Assessment Report Public Assessment Report Hungarian 08-10-2018
Patient Information leaflet Patient Information leaflet Maltese 08-10-2018
Public Assessment Report Public Assessment Report Maltese 08-10-2018
Patient Information leaflet Patient Information leaflet Dutch 08-10-2018
Public Assessment Report Public Assessment Report Dutch 08-10-2018
Patient Information leaflet Patient Information leaflet Polish 08-10-2018
Public Assessment Report Public Assessment Report Polish 08-10-2018
Patient Information leaflet Patient Information leaflet Portuguese 08-10-2018
Summary of Product characteristics Summary of Product characteristics Portuguese 08-10-2018
Public Assessment Report Public Assessment Report Portuguese 08-10-2018
Patient Information leaflet Patient Information leaflet Romanian 08-10-2018
Public Assessment Report Public Assessment Report Romanian 08-10-2018
Patient Information leaflet Patient Information leaflet Slovak 08-10-2018
Public Assessment Report Public Assessment Report Slovak 08-10-2018
Patient Information leaflet Patient Information leaflet Slovenian 08-10-2018
Summary of Product characteristics Summary of Product characteristics Slovenian 08-10-2018
Public Assessment Report Public Assessment Report Slovenian 08-10-2018
Patient Information leaflet Patient Information leaflet Finnish 08-10-2018
Public Assessment Report Public Assessment Report Finnish 08-10-2018
Patient Information leaflet Patient Information leaflet Swedish 08-10-2018
Public Assessment Report Public Assessment Report Swedish 08-10-2018
Patient Information leaflet Patient Information leaflet Norwegian 08-10-2018
Summary of Product characteristics Summary of Product characteristics Norwegian 08-10-2018
Patient Information leaflet Patient Information leaflet Croatian 08-10-2018
Public Assessment Report Public Assessment Report Croatian 08-10-2018

Search alerts related to this product

View documents history